MedTrace Logo

Treatment of Diabetic Neuropathy With Liraglutide

NCT02138045 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-08-10

No results posted yet for this study

Summary

The purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.

Conditions

  • Diabetes Mellitus, Type 1
  • Type 1 Diabetes Mellitus

Interventions

DRUG

Placebo treatment

Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.

DRUG

Liraglutide treatment

Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.

Sponsors & Collaborators

Principal Investigators

  • Asbjørn M. Drewes, Professor · Mech-Sense, Department of Medical Gastroenterology, Aalborg Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138045 on ClinicalTrials.gov